Acadia Pharmaceuticals Inc.
ACADHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Acadia Pharmaceuticals Inc. focuses on Biotechnology services and products. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. With a market capitalization of $3.38B, it sits in mid-cap territory. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Market Cap
$3.38B
Beta
0.89
P/E (TTM)
8.85
P/E (Fwd)
21.43
EPS (TTM)
$2.23
EPS (Fwd)
$0.92
ROE
35.7%
ROA
3.6%
Cash
$956.5M
Total Debt
$73.9M
Free CF
$68.6M
52W Change
-14.2%
Annual Financials
Cash vs Debt
Where ACAD stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ACAD finished 16.77% below its 150-day moving average ($23.79) and 17.40% below its 200-day moving average ($23.97). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACAD overbought or oversold?
At the October 20, 2026 close, ACAD's RSI(14) was 45.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $956.5M in cash comfortably exceeding the $73.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $68.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 35.7% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.6% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $517.2M (2022) to $1.07B (2025), reflecting a 107% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Acadia Pharmaceuticals Inc.'s trajectory.